Company Name, Ticker, Suppliers, else..

Galera Therapeutics Inc (GRTX)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Galera Therapeutics Inc 's

Name: Galera Therapeutics Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GRTX Sales vs. its Competitors Q1 2026

Comparing the current results to its competitors, Galera Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, slower than the combined decrease of the GRTX's competitors by -24.3 %, recorded in the same quarter.

• List of GRTX Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Galera Therapeutics Inc recorded a net loss, as well as most of its competitors.

<< GRTX Stock Performance Comparisons

Galera Therapeutics Inc 's Comment on Competition and Industry Peers

The company previously had a formal agreement with Patheon Manufacturing Services LLC for the production of avasopasem, which was later assumed by Biossil. The company faces potential competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies, and public and private research institutions. Key competitive factors include efficacy, safety, convenience, price, generic competition, and reimbursement availability. The company seeks to protect its proprietary position through patents, trademarks, trade secrets, and technological innovation. Orphan drug exclusivity and patent term restoration under the Hatch-Waxman Act are also relevant to its competitive landscape.

<< See the full list of GRTX competitors

*Market share is calculated based on total revenue.

GRTX's Stock Performance relative to its Competitors

Publicly Traded Peers of Galera Therapeutics Inc

Karyopharm Therapeutics Inc
Share Performance

-78.09%

This Year

Karyopharm Therapeutics Inc

Profile

Karyopharm Therapeutics Inc's business model revolves around developing and commercializing novel therapeutic products to treat various types of cancers and other diseases.

More about Karyopharm Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 45.577 mill.	$ 146.621 mill.	$ -224.740 mill.

Kazia Therapeutics Limited
Share Performance

-1.65%

This Quarter

Kazia Therapeutics Limited

Profile

Kazia Therapeutics Limited is a biotechnology company that focuses on developing and commercializing innovative oncology therapies. Their business model revolves around advancing novel drug candidates, conducting clinical trials, and collaborating with partners to bring their products to market.

More about Kazia Therapeutics Limited's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ 0.042 mill.	$ -20.702 mill.

Kezar Life Sciences Inc
Share Performance

+15.90%

This Year

Kezar Life Sciences Inc

Profile

Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.

More about Kezar Life Sciences Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 53.537 mill.	$ - mill.	$ -45.233 mill.

Mersana Therapeutics inc
Share Performance

-14.41%

One Year

Mersana Therapeutics inc

Profile

Mersana Therapeutics Inc's business model focuses on developing and commercializing novel antibody-drug conjugates (ADCs) for the treatment of cancer.

More about Mersana Therapeutics inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 145.286 mill.	$ 33.180 mill.	$ -70.081 mill.

Nucana Plc
Share Performance

-70.67%

One Year

Nucana Plc

Profile

Nucana Plc is a pharmaceutical company that focuses on developing novel treatments for cancer and other diseases.

More about Nucana Plc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ - mill.	$ -70.922 mill.

15 more competitors available

Sources: Galera Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Monday, September 14, 2026 4:04 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Galera Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.